- Diurnal Group has signed deals with leading outsourced commercial services providers as part of pre-launch activities for Infacort.

The group said these represent significant progress in its commercial pre-launch activities following its first market authorisation submission for Infacort to the European Medicines Agency in December.

The company anticipates market authorisation in late 2017.

Diurnal's ambition is to market Infacort itself in major European territories, thereby retaining the full commercial value of the product.

Consistent with this strategy, Diurnal has signed a service agreement with Ashfield Healthcare, part of UDG Healthcare, to support the company in building sales and medical infrastructure in major European territories.

Ashfield will focus in the next 12 months on establishing a Europe wide network of medical liaison staff to prepare the company for the anticipated launch of Infacort in 2018.

Diurnal has also signed an agreement with Sharp Packaging Services, a global leader in contract packaging for the pharmaceutical and biotechnology industries, which is also part of UDG Healthcare, to bring expertise to ensure the Infacort supply chain is managed by an internationally recognised expert business.

Chief executive Dr Martin Whitaker said: "Following the submission of our regulatory application for Infacort to the EMA and its subsequent validation, we are focused on pre-launch activities for this product in Europe.

"We are confident that the agreements announced today with Ashfield and Sharp, both leading providers of outsourced commercialisation services to the pharmaceutical industry, will help ensure the prompt and effective market introduction of Infacort following its anticipated approval in Europe, another key step in realising our ambition of becoming the world's leading specialty pharma company in endocrinology."

At 9:34am: [LON:DNL] Diurnal Group Plc share price was +2.5p at 122p

Story provided by